Gossamer Bio Long Term Debt

Gossamer Bio (GOSS) currently reports a long-term debt of $200M as of March 2026. That compares with $200M in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Gossamer Bio's long-term debt history and peer comparisons.

Gossamer Bio's long-term debt was unchanged from $200M to $200M — essentially flat versus a year earlier (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gossamer Bio reported $200M in long-term debt as of March 2026. That compares with $200M in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gossamer Bio, and consider following GOSS for alerts when major investors trade the stock.

Gossamer Bio is classified in the Healthcare sector. On long-term debt, it currently shows $200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GOSS with unrelated industries.